Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Ankylosing Spondylitis Market

Ankylosing Spondylitis Market Share

Report ID: GMI10134
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Ankylosing Spondylitis Market Share

The ankylosing spondylitis industry is highly competitive, driven by a range of pharmaceutical companies that offer diverse treatment options aimed at managing this chronic inflammatory disease. Key players in the market include major pharmaceutical firms and biotechnology companies that specialize in developing and marketing therapies tailored to address the underlying mechanisms of ankylosing spondylitis.

Ankylosing Spondylitis Market Companies

Prominent players operating in the ankylosing spondylitis industry include:

AbbVie, Inc.
Amgen, Inc.
Bayer AG
Eli Lilly and Company
Horizon Pharma
Janssen Biotech, Inc.
Merck & Co., Inc.
Novartis AG
PRIMUS PHARMACEUTICALS
Pfizer, Inc.
Sandoz Group AG
UCB, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global ankylosing spondylitis industry was valued at USD 5.9 billion in 2023 and is anticipated to register 8.2% CAGR between 2024 and 2032, driven by increasing advancements in treatment options.

The hospital pharmacies segment is expected to witness 7.9% CAGR through 2032, driven by hospitals' access to advanced therapies for conditions like ankylosing spondylitis.

North America ankylosing spondylitis market is expected to reach USD 4.8 billion by 2032 due to advanced healthcare infrastructure and favorable regulatory environments.

AbbVie, Inc., Amgen, Inc., Bayer AG, Eli Lilly and Company, Horizon Pharma, Janssen Biotech, Inc., Merck & Co., Inc., Novartis AG, PRIMUS PHARMACEUTICALS, Pfizer, Inc., Sandoz Group AG, and UCB, Inc.